MREO — Mereo BioPharma Income Statement
0.000.00%
Last trade - 00:00HealthcareSpeculativeSmall Cap
- $92.24m
- $84.03m
- £36.46m
Annual income statement for Mereo BioPharma, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
C2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0 | 0 | 0 | 36.5 |
| Cost of Revenue | ||||
| Gross Profit | — | — | — | 18.6 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 35.2 | 38.5 | 37.6 | 57.4 |
| Operating Profit | -35.2 | -38.5 | -37.6 | -20.9 |
| Gain / Loss on Sale of Assets | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -37.3 | -41.1 | -166 | 14.2 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -32 | -34.8 | -164 | 12.7 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -32 | -34.8 | -164 | 12.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -32 | -34.8 | -164 | 12.7 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.444 | -0.397 | -0.462 | 0.024 |